PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Sanofi’s efanesoctocog alfa may be game-changer for haemophilia A patients

Phase 3 study demonstrated that efanesoctocog alfa met both primary and secondary endpoints.

Research has demonstrated positive safety, efficacy and pharmacokinetic credentials of Sanofi’s efanesoctocog alfa drug.

The therapy is an investigational treatment for haemophilia A and the data showed that it delivered normal to near-normal factor activity levels for most of the week during a once-a-week dosing pattern.

Haemophilia A is a lifelong, rare and genetic condition affecting the ability of a person’s blood to clot, and occurs in about one in 5,000 male births every year while being uncommon in females. Individuals can experience bleeding episodes that can cause irreversible joint damage, severe pain and life-threatening haemorrhages.

Data from the vital XTEND-1 phase 3 study demonstrated that efanesoctocog alfa – also known as ALTUVIIIO – met both primary and secondary endpoints, showing clinically meaningful prevention of bleeds and superior bleed protection compared to prior factor VIII prophylaxis treatment.

Dietmar Berger, global head of development and chief medical officer at Sanofi, reflected: “We are steadfast in our commitment to developing novel treatment options that have a meaningful impact on patients.”

He added: “We are hopeful that efanesoctocog alfa will help deliver on this goal by offering unprecedented factor activity levels with once-weekly dosing, fulfilling its potential as a best-in-class therapy for haemophilia A.”

Associate professor at Michigan Medicine, Angela Weyand, was excited about the potential of the treatment: “Currently, they often need to make trade-offs between bleed protection and dosing frequency.”

“Based on the XTEND-1 study results assessing efanesoctocog alfa, we have the opportunity to provide near normal factor activity levels for an extended period of time (the majority of a week) with a single dose, which is a first for haemophilia A,” she concluded.

The treatment is now under priority review by the US Food and Drug Administration and a decision will be made later in the year.

The findings were initially published in The New England Journal of Medicine.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026